Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 13
Submit an article Journal homepage
547
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma

Matthew M. Leia Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5348-6065View further author information
ORCID Icon,
Erica Tavaresa Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USAView further author information
,
Evan Buzgob Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Uvette Loua Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-9220-3646View further author information
ORCID Icon,
Noopur Rajec Cancer Center, Massachusetts General Hospital, Boston, MA, USAView further author information
&
Andrew J. Yeec Cancer Center, Massachusetts General Hospital, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0003-3623-7491View further author information
ORCID Icon
Pages 3249-3252 | Received 16 Apr 2022, Accepted 13 Aug 2022, Published online: 29 Aug 2022

References

  • Goldner W. Cancer-Related hypercalcemia. J Oncol Pract. 2016;12(5):426–432.
  • Oyajobi BO. Multiple myeloma/hypercalcemia. Arthritis Res Ther. 2007;9 Suppl 1:S4.
  • Panaroni C, Yee AJ, Raje NS. Myeloma and bone disease. Curr Osteoporos Rep. 2017;15(5):483–498.
  • Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99(9):3144–3152.
  • Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. The Lancet. Oncology. 2018;19(3):370–381.
  • Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471–1479.
  • Dave V, Chiang CY, Booth J, et al. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4–5. Am J Nephrol. 2015;41(2):129–137.
  • Group AKIW. Kidney disease: Improving global outcomes (KDIGO) - Clinical practice guideline for acute kidney injury. Kidney Inter. 2012;2:1–138.
  • Kastritis E, Terpos E, Roussou M, et al. Evaluation of the revised international staging system in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102(3):593–599.
  • Morgan KP, Sun Y, Deal A, et al. Denosumab for First-Line treatment of hypercalcemia associated with malignancy: Retrospective analysis. Journal of Hematology Oncology Pharmacy. 2021;11:121–126.
  • Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558–567.
  • Nasser SM, Sahal A, Hamad A, et al. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: a retrospective cohort study. J Oncol Pharm Pract. 2019;25(8):1846–1852.
  • Menshawy A, Mattar O, Abdulkarim A, et al. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and Meta-analysis of randomized controlled trials. Support Care Cancer. 2018;26(4):1029–1038.
  • Lexicomp Online. Waltham, MA 2022. https://online.lexi.com

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.